ReachRxResearch
Home
Research
Sign Up
To stop or not to stop? International physician survey on HER2 targeted therapy for metastatic breast cancer patients in remission
Back to Research Hub
  1. Home
  2. Research Hub
  3. To stop or not to stop? International ph…

To stop or not to stop? International physician survey on HER2 targeted therapy for metastatic breast cancer patients in remission

The Breast·October 12Open Access
Obstetrics & GynecologyLimited evidenceHER2-Positive Metastatic Breast CancerSurvey StudyHER2-Targeted TherapyAdult

Summary

View source

What was studied

An international physician survey examining decision-making around stopping or continuing HER2-targeted therapy in metastatic breast cancer patients who achieve remission.

Caveats

  • International survey responses may reflect heterogeneous practice guidelines and healthcare systems, reducing generalizability to any single clinical setting
  • Only an abstract or title is available for this paper (published 2026-10-12); no full text was provided, so key results, sample size, and specific findings cannot be extracted
  • Survey-based study design reflects physician opinions and practice patterns rather than clinical outcomes data, limiting direct applicability to patient management decisions

Related Questions

Explore related topics

When is it safe to stop HER2-targeted therapy in metastatic breast cancer patients in complete remission?De-escalation strategies for HER2-positive metastatic breast cancer after achieving remissionPhysician practice patterns for discontinuing trastuzumab or pertuzumab in metastatic HER2-positive breast cancer

Publication Details

Year
2026
Journal
The Breast
Source
View article
Keep scrolling
More content below.
Up Next